forked from neel17/knowledge-graph-text-mining
-
Notifications
You must be signed in to change notification settings - Fork 0
/
pubmed_result.xml
444 lines (442 loc) · 21.4 KB
/
pubmed_result.xml
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">27246822</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>10</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1776-260X</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>11</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2016</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Targeted oncology</Title>
<ISOAbbreviation>Target Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.</ArticleTitle>
<Pagination>
<MedlinePgn>417-28</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s11523-016-0443-8</ELocationID>
<Abstract>
<AbstractText>The BRAF inhibitor dabrafenib (Tafinlar(®)) and the MEK inhibitor trametinib (Mekinist(®)) are indicated, as monotherapy or in combination with each other, for the treatment of patients with unresectable or metastatic melanoma with a BRAF (V600) mutation. This article reviews the therapeutic efficacy and tolerability of combination treatment with dabrafenib and trametinib in this indication and summarizes relevant pharmacological data. Dabrafenib plus trametinib significantly prolonged progression-free survival (PFS) and overall survival (OS), improved objective response rates (ORRs) and preserved health-related quality of life (HR-QOL) to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation. Limited treatment benefit with the combination was also seen in patients who had progressed on prior BRAF inhibitor therapy, as indicated by ORRs of ≤ 15 % and stable disease in ≤ 50 % of patients in small phase I and II studies. Combination therapy did not increase overall toxicity relative to dabrafenib or vemurafenib monotherapy, with most adverse events (AEs) mild or moderate in severity and generally manageable. Fewer skin-related AEs (e.g. cutaneous malignancies, hyperkeratinosis and hand-foot syndrome) were reported with combination therapy than with dabrafenib or vemurafenib, probably because of reduced paradoxical activation of the MAPK pathway. Thus, dabrafenib plus trametinib provides an important treatment option for patients with BRAF (V600) mutation-positive unresectable or metastatic melanoma.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Dhillon</LastName>
<ForeName>Sohita</ForeName>
<Initials>S</Initials>
<AffiliationInfo>
<Affiliation>Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>France</Country>
<MedlineTA>Target Oncol</MedlineTA>
<NlmUniqueID>101270595</NlmUniqueID>
<ISSNLinking>1776-2596</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010091">Oximes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011744">Pyrimidinones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>33E86K87QN</RegistryNumber>
<NameOfSubstance UI="C560077">trametinib</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.11.1</RegistryNumber>
<NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>QGP4HA4G1B</RegistryNumber>
<NameOfSubstance UI="C561627">dabrafenib</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010091" MajorTopicYN="N">Oximes</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011744" MajorTopicYN="N">Pyrimidinones</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2016</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2016</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>10</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">27246822</ArticleId>
<ArticleId IdType="doi">10.1007/s11523-016-0443-8</ArticleId>
<ArticleId IdType="pii">10.1007/s11523-016-0443-8</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>N Engl J Med. 2015 Jan 1;372(1):30-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25399551</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS One. 2013 Jul 03;8(7):e67583</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23844038</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2015 Oct;16(13):1389-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26433819</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2014 Nov 20;32(33):3697-704</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25287827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jul 12;367 (2):107-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22663011</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Pharmacol. 2014;6(3):228</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25745537</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2012 Nov;13(11):1087-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23051966</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Jan 19;366(3):207-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22256804</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Metab Dispos. 2013 Dec;41(12):2215-24</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24097902</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2014 Jun;54(6):696-706</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24408395</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Am Acad Dermatol. 2015 Feb;72(2):221-36; quiz 237-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25592339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2013 Sep;53(9):955-61</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23846776</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2014 Jun 1;120(11):1695-701</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24577748</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Pharmacol. 2013 Sep;53(9):946-54</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23893461</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2014 Nov 13;371(20):1877-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25265492</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2015 Aug 1;386(9992):444-51</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26037941</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Cancer. 2010 Jun 8;102(12):1724-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20531415</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Metab Dispos. 2014 Jul;42(7):1180-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24748562</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Xenobiotica. 2014 Apr;44(4):352-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23971497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pharm Sci. 2013 Sep;102(9):3100-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23608920</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Cancer. 2014 Jul;14(7):455-67</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24957944</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Cancer. 2015 May;51(7):833-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25794603</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Feb 1;31(4):482-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23248257</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2016 Mar 10;34(8):871-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26811525</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Adv Hematol Oncol. 2015 Jul;13(7):451-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26353041</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Oncol. 2015 Mar;27(2):134-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25602684</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Manag Care Spec Pharm. 2014 Apr;20(4):346-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24684639</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Biol Med. 2014 Dec;11(4):237-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25610709</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2015 Aug;16(8):908-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26115796</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2012 Jul 28;380(9839):358-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22735384</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Invest. 2014 May;32(4):144-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24484235</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ther Adv Med Oncol. 2016 Jan;8(1):48-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26753005</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Dermatol Ther (Heidelb). 2015 Sep;5(3):151-69</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26387031</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2012 May 19;379(9829):1893-901</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22608338</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2011 Mar 1;17(5):989-1000</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21245089</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2014 Nov 13;371(20):1867-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25265494</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Br J Clin Pharmacol. 2014 Sep;78(3):524-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24606567</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Commun. 2014 Dec 02;5:5694</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">25452114</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2013 Sep 10;31(26):3205-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23918947</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Oncol. 2015 Sep;26 Suppl 5:v126-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">26314774</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2012 Nov;367 (18):1694-703</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23020132</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2012 Nov 13;22(5):668-82</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23153539</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet Oncol. 2012 Aug;13(8):773-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22805291</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Oncotarget. 2012 Dec;3(12 ):1533-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23237773</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>
</PubmedArticleSet>